Fiche publication
Date publication
octobre 2025
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Ugurel S, Abu Rached N, Gambichler T, Mengoni M, Tüting T, Hassel JC, Reschke R, Lodde GC, Placke JM, Schadendorf D, Reinhardt L, Kreuter A, Gschnell M, Utikal J, Erdmann M, Dücker P, Helbig D, Franklin C, Gebhardt C, Poch G, Kähler KC, Weichenthal M, Gutzmer R, Heinzerling L, Weishaupt C, Mohr P, Thoms KM, Lang B, Schilling B, Haferkamp S, Sachse M, Welzel J, Jochims F, Raap U, Schley G, Terheyden P, Dippel E, Pöttgen C, Becker JC, Tasdogan A, Amaral T, Nanz L, Leiter U
Lien Pubmed
Résumé
For rare skin cancers, few data exist on the outcome of systemic therapies, particularly immune checkpoint inhibition (ICI). The present study analysed the real-world use of different systemic therapies including ICI, and its outcome in patients with advanced rare skin cancers.
Mots clés
Angiosarcoma, Chemotherapy, Cutaneous adnexal carcinoma, Immune checkpoint inhibition, Kaposi sarcoma, Pleomorphic dermal sarcoma, Targeted therapy
Référence
Eur J Cancer. 2025 10 1;228:115750
